Andrew Hinck, PhD

We are interested in using the tools of structural biology to a) uncover the molecular adaptations that proteins of  a highly diversified signaling TGF-beta signaling family have acquired to achieve their unique functions and b) leverage this knowledge to to develop targeted therapies for treating human disease, including soft tissue cancers and tissue fibrosis driven by dysregulated TGF-beta signaling and hereditary hemorrhagic telangiectasia caused by mutations in the receptors and co-receptors for BMP9 and BMP10.